Condition: Metastatic Prostate Cancer · Sponsor: ORIC Pharmaceuticals
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
This description comes directly from the study's public registry record.
ORIC Clinical · 650-388-5600 · clinical@oricpharma.com
Always discuss trial participation with your own doctor first.
| Rocky Mountain Cancer Center | Colorado Springs, Colorado, United States | Recruiting |
| South Florida Oncology and Hematology | Plantation, Florida, United States | Recruiting |
| Illinois Cancer Specialists | Arlington Heights, Illinois, United States | Recruiting |
| Comprehensive Urologic Care | Lake Barrington, Illinois, United States | Recruiting |
| First Urology | Jeffersonville, Indiana, United States | Recruiting |
| Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland | Baltimore, Maryland, United States | Recruiting |
| Maryland Oncology Hematology | Silver Spring, Maryland, United States | Recruiting |
| Karmanos | Detroit, Michigan, United States | Recruiting |
| Minnesota Oncology Hematology | Minneapolis, Minnesota, United States | Recruiting |
| Memorial Sloane Kettering Cancer Center | New York, New York, United States | Recruiting |
| Levine Cancer Institute | Charlotte, North Carolina, United States | Recruiting |
| MidLantic Urology | Bala-Cynwyd, Pennsylvania, United States | Not Yet Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05413421